Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

2

ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

3

ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

4

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

5

Combination Product: ofatumumab with AI
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

6

Combination Product: ofatumumab with PRF
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

7

Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(Arzerra (TN))

[12] Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab (Arzerra),
Ponesimod,
Rituximab,
Teriflunomide

[10] Cladribine ,
Alemtuzumab ,
Rituximab ,
Dimethyl fumarate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab (Arzerra (TN)),
Fingolimod ,
Teriflunomide ,
Ponesimod 💬

Name	Other Names
Cladribine	Cladribine (JAN/USP/INN) Leustatin (TN) Mavenclad (TN)
Alemtuzumab	Alemtuzumab (USAN/INN) Alemtuzumab (genetical recombination) (JAN) Campath (TN) Lemtrada (TN)
Rituximab	Rituximab (USAN/INN) Rituximab (genetical recombination) (JAN) Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN) Rituximab (genetical recombination) [Rituximab biosimilar 2] (JAN) Rituximab-abbs Rituximab-pvvr Rituximab-arrx Rituxan (TN) Riabni (TN) Truximab (TN) RUXIENCE TRUXIMA
Dimethyl fumarate	Dimethyl fumarate (JAN/USAN) Tecfidera (TN)
Ocrelizumab	Ocrelizumab (USAN) Ocrelizumab (genetical recombination) (JAN) Ocrevus (TN)
Natalizumab	Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN)
Ofatumumab	Ofatumumab (USAN/INN) Ofatumumab (genetical recombination) (JAN) Arzerra (TN) Kesimpta (TN)
Fingolimod	Fingolimod (INN) Gilenya (TN)
Teriflunomide	Teriflunomide (USAN) Aubagio (TN)
Ponesimod	Ponesimod (USAN/INN) Ponvory (TN)

[7] CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬

Name	Full Name
CD52	CD52 molecule
DHODH	dihydroorotate dehydrogenase (quinone)
ITGA4	integrin subunit alpha 4
KEAP1	kelch like ECH associated protein 1
MS4A1	membrane spanning 4-domains A1
RRM1	ribonucleotide reductase catalytic subunit M1
S1PR1	sphingosine-1-phosphate receptor 1

[30] Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬

[1] 13 💬

8

OFATUMUMAB
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[3] 13, 35, 46 💬

9

Ofatumumab 100
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

10

Ofatumumab 300
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

11

Ofatumumab 30mg
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

12

Ofatumumab 3mg
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

13

Ofatumumab 60mg
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

14

Ofatumumab 700
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

15

Ofatumumab subcutaneous injection
(Arzerra (TN))

[1] Ofatumumab (Arzerra)

[1] Ofatumumab (Arzerra (TN)) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬